Bolt Biotherapeutics, Inc. Common Stock (BOLT)

Etorro trading 970x250

About Bolt Biotherapeutics, Inc. Common Stock

Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors. Its preclinical stage product candidates include carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. Bolt Biotherapeutics, Inc. was founded in 2015 and is based Redwood city, California. Address: 900 Chesapeake Drive, Redwood City, CA, United States, 94063

Bolt Biotherapeutics, Inc. Common Stock News and around…

Latest news about Bolt Biotherapeutics, Inc. Common Stock (BOLT) common stock and company :

Add Up The Parts: VTWV Could Be Worth $173
22 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $173.25 per unit.

Bolt Biotherapeutics Announces Changes to its Board of Directors
19 Nov, 2021 Yahoo! Finance

REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the appointments of Brian O’Callaghan and Frank D. Lee to the Board of Directors. With these additions, longtime Director Peter Moldt, Ph.D. is stepping down from the Board of Directors and

Bolt Biotherapeutics Presents New Preclinical Data on Three Pipeline Programs at Society for Immunotherapy of Cancer (SITC) Annual Meeting
12 Nov, 2021 Yahoo! Finance

Presentation of preclinical data supporting the selection of BDC-2034, an ISAC targeting CEA, as Bolt Biotherapeutics’ second Boltbody™ ISAC development candidateDemonstration of the novel, multifunctional mechanism for an ISAC which combines PD-1/PD-L1 axis inhibition with TLR agonismIdentification of novel agonist antibodies targeting Dectin-2, now revealed as Bolt Biotherapeutics’ TAM1 target, designed to reprogram tumor-supportive macrophages into tumor-destructive macrophages REDWOOD CITY,

Bolt Biotherapeutics is Now Oversold (BOLT)
10 Nov, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights
09 Nov, 2021 Yahoo! Finance

–BDC-1001 Phase 1/2 dose-escalation interim clinical trial update in HER2-expressing solid tumors to be presented at ESMO Immuno-Oncology Congress 2021–Strong cash position of $295.5 million expected to fund operations through the end of 2023 REDWOOD CITY, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of bo

Bolt Biotherapeutics to Present at Stifel 2021 Virtual Healthcare Conference
08 Nov, 2021 Yahoo! Finance

REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that Randall C. Schatzman, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 1:00 p.m. PT

89bio Announces Appointment of Kathy LaPorte to its Board of Directors
03 Nov, 2021 Yahoo! Finance

SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry lea

Analysts Predict 16% Gains Ahead For The Holdings of VTWV
19 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $168.64 per unit.

Bolt Biotherapeutics to Present Updates on Three Pipeline Programs at the 2021 Society for Immunotherapy of Cancer Annual Meeting (SITC)
01 Oct, 2021 Yahoo! Finance

Three SITC presentations highlight the breadth of immuno-oncology strategies from the company’s expanding portfolioREDWOOD CITY, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that it will be presenting three abstracts at the 2021 Society for I

Peek Under The Hood: VTWV Has 17% Upside
14 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $166.05 per unit.

Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo® for Treatment of HER2-Expressing Solid Tumors
08 Sep, 2021 FinancialContent
Bolt Biotherapeutics to Participate in Upcoming September Investor Conferences
02 Sep, 2021 FinancialContent
Week in Review: Suzhou Abogen Raises $700 Million for mRNA COVID Vaccine
28 Aug, 2021 FinancialContent

COVID-19 Pandemic  Suzhou Abogen Biosciences raised over $700 million in a record-breaking Series C round to support a Phase III trial of its mRNA COVID-19 vaccine; Brii Bio, a Beijing-North Carolina company, said its combination mAb therapy reduced hospitalization and death in early-stage COVID-19 patients by 73%;  Deals and Financing  BeyondSpring, a US-China company, out-licensed China commercialization rights for its lead oncology to Hengrui Pharma in a $200 million agreement; Beijing Kangle Weishi Biotech completed a $157 million pre-IPO financing to develop recombinant vaccines based on its virus-like particle platform; Suzhou Alphamab Oncology out-licensed China rights for its anti-HER2 bispecific antibody to CSPC Pharma in a deal worth up to $150 million; Guangzhou Bio-Thera sold US commercialization rights for its Stelara® biosimilar to Hikma Pharma in a $150 million agreement; Lynk Pharmaceuticals completed a Series B financing of $50 million to conduct Phase I/II clinical trials of its small molecule pipeline; Ocumension Therapeutics of Shanghai acquired China rights for two approved Novartis ophthalmic drugs in a $35 million deal; Suzhou Innovent and San Francisco's Bolt Bio will partner to discover three immune-stimulating antibody conjugate candidates for cancer;  Trials and Approvals  Shanghai Everest Medicines has begun a China Phase III trial of sacituzumab govitecan-hziy in patients with metastatic urothelial cancer; Shanghai Reistone Biopharma reported positive results from a Phase II trial of its JAK1 inhibitor for alopecia areata, an autoimmune disease; LianBio, a Shanghai-Princeton in-licensing company, started a China Phase IIa trial of infigratinib, an FGFR2 inhibitor, for patients with gastric cancers.  Stock Symbols: (HK: 2137) (NSDQ: BYSI) (SHA: 600276) (HK: 9966)  (HK: 1093) (SHA: 688177)  (LSE: HIK) (HK: 1477)  (NYSE: NVS) (HK: 01801) (NSDQ: BOLT) (HK: 1952) Share this with colleagues:

The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
27 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Innovent Biologics, Bolt Join Forces To Develop Anti-Cancer Candidates
27 Aug, 2021 FinancialContent

Innovent Biologics Inc (OTC: IVBIY) and Bolt Biotherapeutics Inc (NASDAQ: BOLT) have entered into a drug research and development ...

Innovent and Bolt Partner to Develop Novel Antibody Conjugate Drugs
27 Aug, 2021 FinancialContent

Suzhou Innovent Bio and San Francisco's Bolt Bio will partner to discover three immune-stimulating antibody conjugate (ISAC) candidates for cancer. The conjugate molecules will combine antibody targeting with the power of the innate and adaptive immune systems. Innovent will apply its discovery capability on undisclosed oncology targets. while Bolt will add its ISAC technology and myeloid biology expertise to initiate a new class of immuno-oncology agents. Bolt will receive an upfront payment of $5 million and is eligible for a $10 million equity investment. More details.... Stock Symbols: (HK: 01801) (NSDQ: BOLT) Share this with colleagues:

Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs
26 Aug, 2021 FinancialContent
Here's Why We're Not Too Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation
16 Aug, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Bolt Biotherapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights
12 Aug, 2021 FinancialContent
Implied VTWV Analyst Target Price: $164
11 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $164.46 per unit.

68 Biggest Movers From Yesterday
10 Aug, 2021 FinancialContent

Gainers Golden Nugget Online Gaming, Inc. (NASDAQ: GNOG) shares climbed 50.8% to close at $18.50 on Monday after the company and ...

European Uber Rival Firm Reaches $4.8B Valuation Following Fundraise For Grocery-Delivery Service: Report
02 Aug, 2021 Yahoo! Finance

Uber Technologies Inc's (NYSE: UBER) European rival, Bolt Technology OU, doubled its valuation to $4.8 billion (€4 billion) after raising money to finance a grocery-delivery service, aiming to capitalize on the pandemic recovery, Bloomberg reported. Bolt, which boasts 75 million customers, raised €600 million from investors, including Sequoia Capital and Tekne Capital Management, to finance a 15-minute grocery delivery service called Bolt Market in 10 European countries few months. Bolt operates

RSI Alert: Bolt Biotherapeutics (BOLT) Now Oversold
29 Jul, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
28 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
27 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Duolingo’s bellwether IPO
23 Jul, 2021 FinancialContent

Hello and welcome back to Equity, TechCrunch’s venture capital-focused podcast, where we unpack the numbers behind the headlines. We were smaller team this week, with Natasha and Alex together with Chris to sort through yet another summer frenzy of a week. This time around we actually recorded live on Twitter Spaces, which was a first for the podcast. […]

Bolt Biotherapeutics, Inc. (BOLT): Are Hedge Funds Right About This Stock?
20 Jul, 2021 Yahoo! Finance

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
16 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Fintech Focus For July 12, 2021
12 Jul, 2021 FinancialContent

Quote To Start The Day: “The real test is not whether you avoid this failure, because you won't. It's whether you let ...

Bolt Biotherapeutics, Inc. Common Stock (BOLT) is a NASDAQ Common Stock listed in , ,

970x250